IP Library Granted Patent US 7,205,274
Granted Patent B2
US 7,205,274 · App. 10/197,000 · Granted Apr 17, 2007

Hybrid peptides modulate the immune response

Assignee: Antigen Express, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,205,274
App. No.
10/197,000
Granted
Apr 17, 2007
Kind
B2
Abstract

The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components.

Claims (16)

1. A method for enhancing presentation by an MHC class II expressing antigen presenting cell of an MHC class II restricted antigenic epitope to a T cell, comprising:

a) incorporating the MHC class II restricted antigenic epitope into an MHC class II antigen presentation enhancing hybrid polypeptide, the hybrid polypeptide comprising;

i) an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) or a truncated form thereof in which the LRMK residues are unaltered and which retains antigen presentation enhancing activity;

ii) a C-terminus comprising the MHC class II restricted antigenic epitope in the form of a polypeptide structure which binds into the antigenic peptide binding site of an MHC class II molecule of an MHC II expressing antigen presenting cell; and

iii) an intervening chemical structure covalently linking the N-terminal and C-terminal components of the hybrid, the chemical structure being a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion; and

b) contacting under physiological conditions:

i) the hybrid polypeptide of step a);

ii) the MHC class II expressing antigen presenting cell; and

iii) a T cell which is responsive to the presentation of the antigenic epitope by the MHC class II molecule of the MHC II expressing antigen presenting cell.

2. The method of claim 1 wherein an MHC class II allelic response to the antigenic epitope is increased.

3. A method for enhancing the range of MHC class II allelic presentation of an allelically restricted antigenic epitope, comprising:

a) incorporating the antigenic epitope into an antigen presentation enhancing hybrid polypeptide, the hybrid polypeptide comprising:

i) an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) or a truncated form thereof comprising at least the LRMK core sequence (SEQ IN NO.: 3), wherein said N-terminus retains antigen presentation enhancing activity;

ii) a C-terminus comprising the antigenic epitope;

iii) an intervening chemical structure covalently linking the N-terminal and C-terminal components of the hybrid, the chemical structure being a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion; and

b) contacting the antigen presentation enhancing hybrid polypeptide of step a) with antigen presenting cells and T lymphocytes which are responsive to the presentation of the antigenic epitope by an MHC class II molecule of the antigen presenting cells, under physiological conditions.

Assignments (6)
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: CRANSHIRE CAPITAL, L.P.
Reel/Frame 020753/0592 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: SMITHFIELD FIDUCIARY LLC
Reel/Frame 020753/0662 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: IROQUOIS CAPITAL OPPORTUNITY FUND, LP
Reel/Frame 020753/0704 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: PORTSIDE GROWTH AND OPPORTUNITY FUND
Reel/Frame 020753/0751 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: ROCKMORE INVESTMENT MASTER FUND LTD.
Reel/Frame 020753/0822 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: IROQUOIS MASTER FUND LTD.
Reel/Frame 020794/0416 →
Continuity (2)
Division 0939681300 · Sep 14, 1999
Related Publication 20030091582A1 · May 15, 2003